Loading
NASDAQHealthcareBiotechnology
Latest quote
$5.115
+$0.075 · +1.49%
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
Regular session
$5.115
+$0.075 · +1.49%
Regular session · ET · Market data may be delayed.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
Day range
Current $5.115
52-week range
Current $5.115
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
47
Fair Value
Sentiment
70
Bullish
Risk
49
Elevated Risk
Momentum
39
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
Day range
Current $5.115
52-week range
Current $5.115
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 216.11M USD | 198.77M USD | 192.64M USD | 254.38M USD | 268.68M USD |
| Cost of goods sold | 13.04M USD | 11.31M USD | 14.8M USD | 24.28M USD | 25.63M USD |
| Gross profit | 203.06M USD | 187.46M USD | 177.84M USD | 230.1M USD | 243.05M USD |
| Research and development | 109.27M USD | 74.43M USD | 76.82M USD | 85.77M USD | 75.36M USD |
| Selling, general, and administrative | 237.95M USD | 146.41M USD | 112.88M USD | 136.49M USD | 124.05M USD |
| Operating expenses | 354.23M USD | 228.12M USD | 191.8M USD | 223.77M USD | 200.89M USD |
| Interest income | — | — | — | — | 199K USD |
| Depreciation and amortization | 11.92M USD | 8.13M USD | 3.01M USD | 2.73M USD | 2.84M USD |
| Operating income | −151.17M USD | −40.66M USD | −13.95M USD | 6.33M USD | 42.17M USD |
| Net income | −220.47M USD | −18.9M USD | 2.51M USD | 6.28M USD | 33.15M USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$21.00
310.56% upsideFunds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI12.36M0.11%11B USD0.35%$156.66-0.10%
Vanguard Morningstar Total Stock Market ETFVTI8.99M0.00%2.3T USD0.03%$376.57+0.89%
iShares Russell 2000 ETFIWM7.19M0.01%77.55B USD0.19%$289.17+0.51%
Vanguard Extended Market ETFVXF3.6M0.00%93.7B USD0.05%$237.87+0.72%
iShares Russell 2000 Value ETFIWN2.69M0.02%14.28B USD0.24%$219.86+0.40%
iShares Biotechnology ETFIBB2.25M0.02%10.3B USD0.44%$203.47+0.41%
Vanguard U.S. Momentum Factor ETFVFMO1.57M0.08%1.8B USD0.13%$228.93+1.03%
Vanguard Russell 2000 ETFVTWO1.54M0.01%17.4B USD0.06%$116.89+0.47%State Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBVanguard U.S. Momentum Factor ETFVFMOVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
